Advertisement

Anal Intraepitheial Neoplasia

  • Amy L. Lightner
  • Cindy J. Kin
  • Mark L. WeltonEmail author
Chapter

Abstract

The ultimate goals of treating patients with high-grade squamous intraepithelial lesion (HSIL) are preventing morbidity associated with the treatment of anal cancer and mortality from anal cancer itself without causing disturbances of anal function, i.e., continence of stools and flatus. Fortunately, there are low cost, outpatient tools to treat HSIL, and evidence to support their effectiveness in preventing Anal squamous cell carcinoma (ASCC). Although there is an ongoing trial looking at surveillance rather than treatment for HSIL, at this time, treatment should be endorsed especially given its ease to perform. Ultimately, prevention, screening, and treatment of anal HSIL should be as widespread as that for cervical dysplasia. But to achieve this goal, clinicians need to be educated and dedicated to the eradication of this disease; that includes learning high resolution anoscopy (HRA) and willingness to follow patients longitudinally. Hopefully, in the future, rates of ASCC will be minimized with the use of Human papilloma virus (HPV) vaccine and screening for HSIL.

Keywords

High-grade squamous intraepithelial lesion High resolution anoscopy Anal intraepitheial neoplasia Human papilloma virus Anal squamous cell carcinoma Anal cancer 

References

  1. 1.
    Berry JM, Jay N, Cranston RD, et al. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. Int J Cancer. 2014;134(5):1147–55.CrossRefGoogle Scholar
  2. 2.
    Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg. 2005;92(9):1133–6.CrossRefGoogle Scholar
  3. 3.
    Watson AJ, Smith BB, Whitehead MR, Sykes PH, Frizelle FA. Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg. 2006;76(8):715–7.CrossRefGoogle Scholar
  4. 4.
    Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–8.CrossRefGoogle Scholar
  5. 5.
    Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271):1831–6.CrossRefGoogle Scholar
  6. 6.
    Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis. 2001;184(6):682–90.CrossRefGoogle Scholar
  7. 7.
    Critchlow CW, Surawicz CM, Holmes KK, et al. Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS. 1995;9(11):1255–62.CrossRefGoogle Scholar
  8. 8.
    Del Mistro A, Insacco E, Cinel A, Bonaldi L, Minucci D, Chieco-Bianchi L. Human papillomavirus infections of the genital region in human immunodeficiency virus seropositive women: integration of type 16 correlates with rapid progression. Eur J Gynaecol Oncol. 1994;15(1):50–8.PubMedGoogle Scholar
  9. 9.
    Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–65.CrossRefGoogle Scholar
  10. 10.
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefGoogle Scholar
  11. 11.
    Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009;124(10):2375–83.CrossRefGoogle Scholar
  12. 12.
    Devaraj B, Cosman BC. Expectant management of anal squamous dysplasia in patients with HIV. Dis Colon Rectum. 2006;49(1):36–40.CrossRefGoogle Scholar
  13. 13.
    D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2008;48(4):491–9.CrossRefGoogle Scholar
  14. 14.
    Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026–34.CrossRefGoogle Scholar
  15. 15.
    Darragh TM, Colgan TJ, Cox JT, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136(10):1266–97.CrossRefGoogle Scholar
  16. 16.
    Welton MLSS, Goodman KA, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2016. p. 275–84.Google Scholar
  17. 17.
    Abramowitz L, Jacquard AC, Jaroud F, et al. Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer. 2011;129(2):433–9.CrossRefGoogle Scholar
  18. 18.
    Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46(4 Suppl):S20–6.CrossRefGoogle Scholar
  19. 19.
    Wong AK, Chan RC, Aggarwal N, Singh MK, Nichols WS, Bose S. Human papillomavirus genotypes in anal intraepithelial neoplasia and anal carcinoma as detected in tissue biopsies. Mod Pathol. 2010;23(1):144–50.CrossRefGoogle Scholar
  20. 20.
    Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–43.CrossRefGoogle Scholar
  21. 21.
    Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401–11.CrossRefGoogle Scholar
  22. 22.
    Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.CrossRefGoogle Scholar
  23. 23.
    Chin-Hong PV, Berry JM, Cheng SC, et al. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med. 2008;149(5):300–6.CrossRefGoogle Scholar
  24. 24.
    Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS. 1998;12(5):495–503.CrossRefGoogle Scholar
  25. 25.
    Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM. Treatment options for perianal Bowen’s disease: survery of American Society of Colon and Rectal Surgeons Members. Am Surg. 2000;66(7):686–8.PubMedGoogle Scholar
  26. 26.
    Brown SR, Skinner P, Tidy J, Smith JH, Sharp F, Hosie KB. Outcome after surgical resection for high-grade anal intraepithelial neoplasia (Bowen’s disease). Br J Surg. 1999;86(8):1063–6.CrossRefGoogle Scholar
  27. 27.
    Cranston RD, Baker JR, Liu Y, Wang L, Elishaev E, Ho KS. Topical application of trichloroacetic acid is efficacious for the treatment of internal anal high-grade squamous intraepithelial lesions in HIV-positive men. Sex Transm Dis. 2014;41(7):420–6.CrossRefGoogle Scholar
  28. 28.
    Goldstone SE, Hundert JS, Huyett JW. Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males. Dis Colon Rectum. 2007;50(5):565–75.CrossRefGoogle Scholar
  29. 29.
    Stier EA, Goldstone SE, Berry JM, et al. Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an AIDS malignancy consortium pilot study. J Acquir Immune Defic Syndr. 2008;47(1):56–61.CrossRefGoogle Scholar
  30. 30.
    Weis SE, Vecino I, Pogoda JM, Susa JS. Treatment of high-grade anal intraepithelial neoplasia with infrared coagulation in a primary care population of HIV-infected men and women. Dis Colon Rectum. 2012;55(12):1236–43.CrossRefGoogle Scholar
  31. 31.
    Marks DK, Goldstone SE. Electrocautery ablation of high-grade anal squamous intraepithelial lesions in HIV-negative and HIV-positive men who have sex with men. J Acquir Immune Defic Syndr. 2012;59(3):259–65.CrossRefGoogle Scholar
  32. 32.
    Pineda CE, Berry JM, Welton ML. High resolution anoscopy and targeted treatment of high-grade squamous intraepithelial lesions. Dis Colon Rectum. 2006;49(1):126.CrossRefGoogle Scholar
  33. 33.
    Graham BD, Jetmore AB, Foote JE, Arnold LK. Topical 5-fluorouracil in the management of extensive anal Bowen’s disease: a preferred approach. Dis Colon Rectum. 2005;48(3):444–50.CrossRefGoogle Scholar
  34. 34.
    Fox PA, Nathan M, Francis N, et al. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS. 2010;24(15):2331–5.PubMedGoogle Scholar
  35. 35.
    Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol. 2013;14(4):346–53.CrossRefGoogle Scholar
  36. 36.
    Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients. J Gastrointest Surg. 2007;11(11):1410–5. discussion 1415-1416CrossRefGoogle Scholar
  37. 37.
    Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum. 2008;51(6):829–35. discussion 835-827CrossRefGoogle Scholar
  38. 38.
    Richel O, Wieland U, de Vries HJ, et al. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men. Br J Dermatol. 2010;163(6):1301–7.CrossRefGoogle Scholar
  39. 39.
    Shah SB, Pickham D, Araya H, et al. Prevalence of anal dysplasia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13(11):1955.e1951–61.e1951.CrossRefGoogle Scholar
  40. 40.
    Goldstone RN, Goldstone AB, Russ J, Goldstone SE. Long-term follow-up of infrared coagulator ablation of anal high-grade dysplasia in men who have sex with men. Dis Colon Rectum. 2011;54(10):1284–92.CrossRefGoogle Scholar
  41. 41.
    Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum. 2002;45(4):453–8.CrossRefGoogle Scholar
  42. 42.
    Marchesa P, Fazio VW, Oliart S, Goldblum JR, Lavery IC. Perianal Bowen’s disease: a clinicopathologic study of 47 patients. Dis Colon Rectum. 1997;40(11):1286–93.CrossRefGoogle Scholar
  43. 43.
    Snyder SM, Siekas L, Aboulafia DM. Initial experience with topical fluorouracil for treatment of HIV-associated anal intraepithelial neoplasia. J Int Assoc Phys AIDS Care. 2011;10(2):83–8.CrossRefGoogle Scholar
  44. 44.
    Wieland U, Brockmeyer NH, Weissenborn SJ, et al. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol. 2006;142(11):1438–44.CrossRefGoogle Scholar
  45. 45.
    Kreuter A, Hochdorfer B, Stucker M, et al. Treatment of anal intraepithelial neoplasia in patients with acquired HIV with imiquimod 5% cream. J Am Acad Dermatol. 2004;50(6):980–1.CrossRefGoogle Scholar
  46. 46.
    van der Snoek EM, den Hollander JC, van der Ende ME. Imiquimod 5% cream for five consecutive days a week in an HIV-infected observational cohort up to 32 weeks in the treatment of high-grade squamous intraepithelial lesions. Sex Transm Infect. 2015;91(4):245–7.CrossRefGoogle Scholar
  47. 47.
    Singh JC, Kuohung V, Palefsky JM. Efficacy of trichloroacetic acid in the treatment of anal intraepithelial neoplasia in HIV-positive and HIV-negative men who have sex with men. J Acquir Immune Defic Syndr. 2009;52(4):474–9.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Welton ML, Raju NL. Anal Cancer In: Beck DE, Roberts PL, Saclarides TJ, Senagore AJ, Stamos MJ, Wexner SD, editors. The ASCRS textbook of colon and rectal surgery. 2nd ed. New York: Springer; 2011. p. 337–57.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Amy L. Lightner
    • 1
  • Cindy J. Kin
    • 2
  • Mark L. Welton
    • 3
    Email author
  1. 1.Department of Colon and Rectal SurgeryCleveland ClinicClevelandUSA
  2. 2.Department of SurgeryStanford University School of MedicineStanfordUSA
  3. 3.Fairview Health Services, Corporate Department and Department of SurgeryUniversity of MinnesotaMinneapolisUSA

Personalised recommendations